STOK (Stoke Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by STOK officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-03 | Barry Ticho | CHIEF MEDICAL OFFICER | Sell | — | — |
| 2026-08-18 | Edward M. MD Kaye | Director | MIXED | — | — |
| 2026-08-18 | Barry Ticho | CHIEF MEDICAL OFFICER | MIXED | — | — |
| 2026-08-18 | Jonathan Allan | GENERAL COUNSEL & CORP SEC | MIXED | — | — |
| 2026-08-05 | Barry Ticho | CHIEF MEDICAL OFFICER | Sell | — | — |
| 2026-07-17 | Thomas McCauley | Chief Scientific Officer | A | — | — |
| 2026-07-17 | Seth Loring Harrison | Director | G | — | — |
| 2026-07-06 | Barry Ticho | CHIEF MEDICAL OFFICER | Sell | — | — |
| 2026-06-18 | Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sell | — | — |
| 2026-06-05 | Jennifer Burstein | Director | A | — | — |
| 2026-06-05 | Edward M. MD Kaye | Director | A | — | — |
| 2026-06-05 | Seth Loring Harrison | Director | A | — | — |
| 2026-06-05 | ARTHUR TZIANABOS | Director | A | — | — |
| 2026-06-05 | Julie Smith | Director | A | — | — |
| 2026-06-05 | Adrian R. Krainer | Director | A | — | — |
| 2026-06-05 | ARTHUR A LEVIN | Director | A | — | — |
| 2026-06-03 | Barry Ticho | CHIEF MEDICAL OFFICER | Sell | — | — |
| 2026-05-05 | Barry Ticho | CHIEF MEDICAL OFFICER | Sell | — | — |
| 2026-04-07 | Clare Kahn | Director | A | — | — |
| 2026-04-03 | Barry Ticho | CHIEF MEDICAL OFFICER | Sell | — | — |
| 2026-03-24 | Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sell | — | — |
| 2026-03-19 | Jason Hoitt | Chief Patient Officer | Sell | — | — |
| 2026-03-19 | Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sell | — | — |
| 2026-03-19 | Thomas Leggett | Chief Financial Officer | Sell | — | — |
| 2026-03-19 | Barry Ticho | CHIEF MEDICAL OFFICER | MIXED | — | — |
| 2026-03-17 | Thomas Leggett | Chief Financial Officer | M | — | — |
| 2026-03-17 | ARTHUR A LEVIN | Director | Sell | — | — |
| 2026-03-17 | Jonathan Allan | GENERAL COUNSEL & CORP SEC | M | — | — |
| 2026-03-17 | Jason Hoitt | Chief Patient Officer | M | — | — |
| 2026-03-17 | Edward M. MD Kaye | Director | M | — | — |
| 2026-03-17 | Barry Ticho | CHIEF MEDICAL OFFICER | M | — | — |
| 2026-03-12 | Adrian R. Krainer | Director | Sell | — | — |
| 2026-03-12 | ARTHUR TZIANABOS | Interim Executive Chair | MIXED | — | — |
| 2026-03-04 | Adrian R. Krainer | Director | Sell | — | — |
| 2026-02-19 | Jason Hoitt | Chief Patient Officer | A | — | — |
| 2026-02-19 | IAN F SMITH | Chief Executive Officer | A | — | — |
| 2026-02-19 | Barry Ticho | CHIEF MEDICAL OFFICER | A | — | — |
| 2026-02-19 | Thomas Leggett | Chief Financial Officer | A | — | — |
| 2026-02-19 | Jonathan Allan | GENERAL COUNSEL & CORP SEC | A | — | — |
| 2026-01-05 | ARTHUR A LEVIN | Director | M | — | — |
| 2025-12-10 | Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sell | — | — |
| 2025-12-10 | Edward M. MD Kaye | Director | Sell | — | — |
| 2025-12-05 | Jonathan Allan | GENERAL COUNSEL & CORP SEC | MIXED | — | — |
| 2025-12-05 | Edward M. MD Kaye | Director | MIXED | — | — |
| 2025-12-05 | Barry Ticho | CHIEF MEDICAL OFFICER | MIXED | — | — |
| 2025-12-03 | Barry Ticho | CHIEF MEDICAL OFFICER | MIXED | — | — |
| 2025-12-03 | Jonathan Allan | GENERAL COUNSEL & CORP SEC | MIXED | — | — |
| 2025-12-03 | Edward M. MD Kaye | Director | MIXED | — | — |
| 2025-11-26 | Adrian R. Krainer | Director | Sell | — | — |
| 2025-11-18 | Adrian R. Krainer | Director | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 17,161,713 | — |
| — | 10%+ Owner | 10,843,681 | — |
| — | 10%+ Owner | 3,906,181 | — |
| — | 10%+ Owner | 3,560,682 | — |
| — | 10%+ Owner | 3,544,248 | — |
| — | 10%+ Owner | 671,808 | — |
| — | Director | 283,302 | — |
| — | Director | 124,557 | — |
| — | Interim Executive Chair | 35,694 | — |
| — | EVP Research & Preclinical Dev | 26,546 | — |
| — | Former CFO | 24,862 | — |
| — | Director | 22,216 | — |
| — | GENERAL COUNSEL & CORP SEC | 21,225 | — |
| — | CHIEF MEDICAL OFFICER | 20,110 | — |
| — | Chief Financial Officer | 13,476 | — |
| — | Chief Patient Officer | 12,207 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the STOK quote page; the site-wide leaderboard is on the insider transactions hub.